1. Baldessarini, R.J., 1996, Drugs and the treatment of psychiatric disorders, in: The Pharmacological Basis of Therapeutics, 9th edn., eds. J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon and A.G. Gilman, p. 399.
2. Baldessarini, R.J., D. Hulston-Lyons, A. Campbell, E. Marsh and B.M. Cohen, 1992, Do central antiadrenergic actions contribute to the atypical properties of clozapine?, Br. J. Pharmacol. 160 (Suppl. 17), 12.
3. Beasley, C.M., G. Tollefson, P. Tran, W. Satterlee, T. Sanger, S. Hamilton and the Olanzapine HGAD Study Group, 1996, Olanzapine versus placebo and haloperidol, acute phase results of the North American double-blind olanzapine trial, Neuropsychopharmacology 14, 111.
4. Bersani, G., A. Grispini, S. Marini, A. Pasini, M. Valducci and N. Ciani, 1986, Neuroleptic-induced extrapyramidal side-effects: clinical perspectives with ritanserin (R 55 667), a new selective 5-HT2 receptor blocking agent, Curr. Ther. Res. 40, 492.
5. Borison, R.L., F.J. Huff, J. Veraklis, L. Griffiths, R. Ramaswamy and J. Shipley, 1995, Efficacy of 2 and 4 mg BID iloperidone (HP 873) administered to schizophrenic patients for 42 days, ACNP Abstr. 34, 135.